EDGEMOND JAMES sold $180K of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 320 shares of UNITED THERAPEUTICS Corp (UTHR) at $561.48 ($0.18M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider activity but does not, by itself, indicate a change in company fundamentals given the pre-arranged nature of the trade.
Market read
Near-term sentiment could dip on the headline of insider selling, but the 10b5-1 framing generally limits interpretive impact.
What to watch
Traders should check whether multiple insiders are selling/buying around the same period and whether there are concurrent fundamental catalysts not mentioned in the Form 4.
Background
SEC Form 4 insider transaction: CFO/treasurer sold 320 shares at ~$561.48 on 2026-05-28 under a pre-arranged Rule 10b5-1 plan.
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold $179.7K of UTHR shares via an open-market transaction under a 10b5-1 plan.
Limited, mostly sentiment-driven; any impact likely fades unless accompanied by other negative company news.
The filing is an ownership-change disclosure with a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity without any stated drug/clinical or regulatory catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may be routine liquidity rather than bearish information; price reaction may be overstated.
Key entities
- issuerUnited Therapeutics Corp
Subject of the SEC Form 4 insider sale by CFO/treasurer Edgemond James.
- insiderEdgemond James
CFO and treasurer who executed the open-market sale under a 10b5-1 plan.
